Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of MY102979ApublicationCriticalpatent/MY102979A/en
THE PRESENT INVENTION PROVIDES A SUGAR DERIVATIVE OF A BIOLOGICALLY ACTIVE PEPTIDE, WHICH DERIVATIVE HAS A PROLONGED DURATION OF ACTION WHEN COMPARED TO THE NON-SUGAR MODIFIED PEPTIDE, AND CONTAINS AT LEAST ON ONE OF THE AMINO ACID UNITS A SUGAR RESIDUE WHICH IS ATTACHED TO AN AMINO GROUP THEREOF BY A COUPLING OTHER THAN A DIRECT N-GLYCOSIDIC BOND, AND ADDITIONALLY, WHEN IT IS A CONDENSATION PRODUCT OF A CARBOXYL GROUP CONTAINING SUGAR AND A PEPTIDE WITH LESS THAN 8 AMINO ACID UNITS, BY A COUPLING OTHER THAN A DIRECT AMIDE BOND.
GAMMA), ITS VEHICLES OF POLYPEPTIDES CONTAINING THE EXPRESSION SEQUENCE, THEIR PROCEDURE OF INTERFERON AMINO ACIDS PREPARATION, HUMAN IMMUNE COMPOSITIONS (HUMAN INTERFERON PHARMACEUTICALS CONTAINING SUCH POLYPEPTIDES.
1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo(or oxo)-5-pyrimidine-carboxylic acids and esters and pharmaceutical compositions containing the same
Tricyclic derivative, namely 5-(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo[C,F] [1,2]-thiazepin-11-ylamino)-pentanoic acid, process for its preparation and medicines and medicines containing it.